A M Müller1, C S Osório2, D R Silva3, G Sbruzzi1, P de Tarso, Roth Dalcin3. 1. Universidade Federal do Rio Grande do Sul (UFRGS), Programa de Pós Graduação em Ciências Pneumológicas, UFRGS, Porto Alegre, Rio Grande do Sul. 2. Universidade Federal do Rio Grande do Sul (UFRGS). 3. Universidade Federal do Rio Grande do Sul (UFRGS), Programa de Pós Graduação em Ciências Pneumológicas, UFRGS, Porto Alegre, Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
Abstract
SETTING: One of the most serious problems in tuberculosis (TB) control is non-adherence to treatment. Several strategies have been developed to improve adherence and increase the cure rate. OBJECTIVE: To systematically review interventions to improve adherence to anti-tuberculosis treatment. DESIGN: We performed a systematic review and meta-analysis of 22 randomised clinical trials (RCTs) to ascertain whether providing directly observed treatment, short-course (DOTS), financial incentives, food incentives and/or patient education/counselling improved adherence to anti-tuberculosis treatment. The primary outcome was cure rate; secondary outcomes were default and mortality rates. Sources used were Medline (accessed via PubMed), Cochrane Central, LILACS (Literatura Latino Americana em Ciências da Saúde, Latin American and Caribbean Health Sciences Literature) and Embase from inception to October 2015. RESULTS: A significant increase in cure rates, by 18% with DOTS and by 16% with patient education and counselling, was observed. In addition, the default rate decreased by 49% with DOTS, by 26% with financial incentives and by 13% with patient education and counselling. There was no statistically significant reduction in mortality rates with these interventions. CONCLUSION: Use of DOTS and patient education/counselling significantly improved cure rates; DOTS, patient education/counselling and financial incentives led to a reduction in the default rate.
SETTING: One of the most serious problems in tuberculosis (TB) control is non-adherence to treatment. Several strategies have been developed to improve adherence and increase the cure rate. OBJECTIVE: To systematically review interventions to improve adherence to anti-tuberculosis treatment. DESIGN: We performed a systematic review and meta-analysis of 22 randomised clinical trials (RCTs) to ascertain whether providing directly observed treatment, short-course (DOTS), financial incentives, food incentives and/or patient education/counselling improved adherence to anti-tuberculosis treatment. The primary outcome was cure rate; secondary outcomes were default and mortality rates. Sources used were Medline (accessed via PubMed), Cochrane Central, LILACS (Literatura Latino Americana em Ciências da Saúde, Latin American and Caribbean Health Sciences Literature) and Embase from inception to October 2015. RESULTS: A significant increase in cure rates, by 18% with DOTS and by 16% with patient education and counselling, was observed. In addition, the default rate decreased by 49% with DOTS, by 26% with financial incentives and by 13% with patient education and counselling. There was no statistically significant reduction in mortality rates with these interventions. CONCLUSION: Use of DOTS and patient education/counselling significantly improved cure rates; DOTS, patient education/counselling and financial incentives led to a reduction in the default rate.
Authors: Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth Journal: Am J Respir Crit Care Med Date: 2019-11-15 Impact factor: 21.405
Authors: Antonia Morita I Saktiawati; Marcel Harkema; Althaf Setyawan; Yanri W Subronto; Ymkje Stienstra; Rob E Aarnoutse; Cecile Magis-Escurra; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar; Marieke G G Sturkenboom Journal: Clin Pharmacokinet Date: 2019-11 Impact factor: 6.447
Authors: Sarah J Iribarren; Hannah Milligan; Cristina Chirico; Kyle Goodwin; Rebecca Schnall; Hugo Telles; Alejandra Iannizzotto; Myrian Sanjurjo; Barry R Lutz; Kenneth Pike; Fernando Rubinstein; Marcus Rhodehamel; Daniel Leon; Jesse Keyes; George Demiris Journal: Lancet Reg Health Am Date: 2022-06-10
Authors: Alexandra J Zimmer; Petra Heitkamp; James Malar; Cintia Dantas; Kate O'Brien; Aakriti Pandita; Robyn C Waite Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-06-25